Table 2. Years 1988-2002a summary of experimental FIV vaccines.
|
|
Vaccine type | Protective efficacy |
|
|
Conventional vaccines | |
Inactivated whole virus | Homologous and heterologous protection |
Inactivated FIV-infected cells (ICV) | Homologous and heterologous protection |
Subunit vaccines | |
Purified p24 (Gag core) protein | No protection |
Synthetic Env V3 (variable-3 domain) peptide | No protection |
Synthetic Env C2 (constant-2 domain) peptide | No protection |
Baculovirus expressed SU gp100 | No protection but a decrease in virus load observed in one study |
E. coli expressed SU p100 | No protection but a decrease in virus load observed in one study |
E. coli expressed SU V3 | No protection |
Feline herpresvirus-vectored env | No protection |
Adenovirus-vectored env | No protection |
Canarypox virus-vectored gag-pol-env (+/- ICV) | No protection |
DNA vaccines | |
Proviral FIVPET DRT DNA (+/- feline IFNg DNA) | Some homologous protection but not repeatable |
Proviral FIVPPR DVIF | Homologous protection |
Proviral FIVTM2 DAP1 DNA | Homologous protection |
Proviral FIVGL8 DRT DNA (+/- feline IL-12 and/or IL-18 DNA) | No protection |
Proviral FIVGL8 DIN DNA (+/- feline IL-12 and/or IL-18 DNA) | Minimal protection against heterologous FIVPET but only decrease in viral load against homologous FIVGL8 |
FIVZ2 gp140 DNA MIDGE (+/- feline IL-12 DNA MIDGE) | Homologous protection |
FIVZ2 gp140 DNA MIDGE (+/- feline IL-16 DNA MIDGE) | No homologous protection but decrease in viral load |
Plasmid pC1-p24 DNA (+/- recombinant SU gp100) | No protection |
|